The trial profile is shown in Fig. 1.
The baseline and post-treatment group mean values ± SD for symptom scores, bodyweight,, and FEV /FVC% are given in Table 2. The number of patients with different grades of sputum microscopy, sputum culture (based on 13 subjects in the yoga group and 19 subjects in the control group), and CXR for both groups on days 1 and 60 are shown in Table 3.
The two study groups were similar at baseline with respect to symptom scores, bodyweight, FEV and FEV /FVC% ( P> 0.05, unpaired t-test). The difference between the FVC values of the two groups at baseline was close to being significant ( P = 0.05, unpaired t-test). At baseline the grades of sputum microscopy, culture, and CXR were not significantly different ( P> 0.05, McNemar’s test for significance of change). No patient had a negative or clear CXR at baseline.
The paired t-test was used to compare values on day 60 with those on day 1 for each of the groups separately for the following: (i) symptom scores; (ii) bodyweight; (iii) FVC; (iv) FEV, and (v) FEV/FVC%. The yoga group showed a significant decrease in symptom scores ( P= 0.001, 88.1%), increase in bodyweight (P= 0.001, 10.9%), increase in FVC ( P= 0.001, 64.7%), and FEV (P= 0.001, 83.6%). The breath awareness group also showed a significant reduction in symptom scores (P= 0.02, 16.3%), increase in bodyweight (P= 0.003, 2.1%), and increase in FEV (P= 0.04, 63.8%), but no change in FVC.

Comparing the number of patients in the two groups who improved, who showed no change or who yoga group and in 3/22 in the breath awareness group (P = 0.001). With respect to patient compliance, there was no significant difference between the numbers of participants in the yoga group compared to the number from the breath awareness group who returned for drug collection every month until the fourth month (14 vs 15, respectively).